Abstract

Background

We aimed to investigate the efficacy and tolerability of ultra-hypofractionated radiotherapy (UHRT) in the treatment of low and intermediate-risk prostate cancer patients.

Methods

This retrospective study was conducted using data derived from 44 patients who underwent UHRT, and toxicity assessment and clinical response were investigated. Treatment consisted of 35–36.25 Gy in 5 fractions using stereotactic ablative radiotherapy (SABR) with the Linac-based delivery system.

Results

The median duration of follow-up was 52 months (8–68 months) and the median age was 71.5 years (54–85 years). Twenty-seven patients were assigned as intermediate-risk, whereas 17 patients had low-risk. The 5-year overall survival rate was 87.8%, while the 5-year biochemical recurrence-free survival (bRFS) rate was 97.4%. Acute grade 3 genitourinary (GU) side effect was not observed in any patient, whereas acute gastrointestinal (GI) system grade 3 side effect was seen in 6.8% of the patients. Late grade 3 GU and GI side effects were seen in 4.6% and 6.8% of the patients, respectively. In patients with planning target volume (PTV) ≥85 ml, acute grade ≥2 GU side effects were more common (p=.034).

Conclusion

Our data demonstrated that UHRT administered with volumetric arc therapy (VMAT) can be recommended for selected patients with low-intermediate risk prostate cancer. Further prospective, multicentric, controlled trials on larger series are warranted to reach more accurate conclusions.

中文翻译：

---

超大分割放疗在低中危前列腺癌患者中的疗效和耐受性：单中心经验

摘要

背景

我们旨在研究超大分割放射治疗 (UHRT) 在治疗中低危前列腺癌患者中的疗效和耐受性。

方法

这项回顾性研究使用来自接受 UHRT 的 44 名患者的数据进行，并对毒性评估和临床反应进行了调查。治疗包括 35-36.25 Gy，分 5 次使用立体定向消融放射治疗 (SABR) 和基于直线加速器的输送系统。

结果

中位随访时间为 52 个月（8-68 个月），中位年龄为 71.5 岁（54-85 岁）。27 名患者被分配为中等风险，而 17 名患者被分配为低风险。5年总生存率为87.8%，5年生化无复发生存率（bRFS）为97.4%。在任何患者中均未观察到急性 3 级泌尿生殖 (GU) 副作用，而在 6.8% 的患者中观察到急性胃肠 (GI) 系统 3 级副作用。分别有 4.6% 和 6.8% 的患者出现 3 级晚期 GU 和 GI 副作用。在计划目标体积 (PTV) ≥85 ml 的患者中，≥2 级 GU 的急性副作用更为常见 ( p =.034)。

结论

我们的数据表明，UHRT 与体积弧治疗 (VMAT) 可以推荐用于选定的中低风险前列腺癌患者。有必要对更大系列的进一步前瞻性、多中心、对照试验得出更准确的结论。